Patent cliff: Difference between revisions
From ACT Wiki
Jump to navigationJump to search
imported>Doug Williamson (Create page. Source: FiercePharma webpage https://www.fiercepharma.com/pharma/big-pharma-faces-26-5b-patent-loss-threats-year-analyst-says) |
imported>Doug Williamson (Add link.) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
* [[Patent]] | * [[Patent]] | ||
* [[Pharma]] | * [[Pharma]] | ||
* [[Pharmaceuticals]] | |||
* [[Trademark]] | * [[Trademark]] | ||
[[Category:The_business_context]] | |||
Latest revision as of 19:59, 2 July 2021
A patent cliff is a sudden and substantial drop in sales, on the expiry of a patent.
Patent cliffs are particularly significant in the pharmaceutical industry.
